Amgen(US:AMGN) Ge Long Hui·2026-02-04 15:35Core Insights - Amgen (AMGN.US) shares rose over 5%, reaching a record high of $356.5 [1] Financial Performance - In Q4 of the previous year, Amgen reported a revenue increase of 9% year-over-year to $9.87 billion, surpassing analyst expectations of $9.47 billion [1] - Net profit surged over 112% year-over-year to $1.33 billion, with adjusted earnings per share (EPS) of $5.29, significantly exceeding the analyst forecast of $4.73 [1] Future Outlook - For the current year, Amgen projects revenue between $37 billion and $38.4 billion, with adjusted EPS expected to be between $21.6 and $23, compared to analyst expectations of $37.19 billion and $20.63 [1] - The company plans to initiate Phase III clinical trials for Maritide targeting patients with type 2 diabetes this year [1]